Aduhelm's accelerated approval offers a promising roadmap for rare neurological diseases
By Emil Kakkis
FDA head urges probe of agency's dealings with Biogen, maker of controversial new Alzheimer's drug
By Laurie McGinley
Biogen, FDA walk back controversial Aduhelm label after weeks of fierce criticism
By Noah Higgins-Dunn
In Reversal, F.D.A. Calls for Limits on Who Gets Alzheimer's Drug (Published 2021)
By Pam Belluck & Rebecca Robbins